Health Care·Biotechnology·$351.5B
AbbVie Inc. is a global biopharmaceutical company that focuses on developing innovative therapies for complex diseases....
EPS
Earnings per share is a critical measure of profitability and will indicate how well AbbVie is managing its costs and revenues.
Revenue
Total revenue gives insight into the company's overall sales performance and market demand for its products.
Wall Street expectations, options signals, track record, and call prep available with Pro.
EPS Beat Streak
2Q
EPS Beat Rate
75%
Avg EPS Surprise
+0.86%
Avg Stock Reaction
+0.58%
In Q4 2025, AbbVie reported an EPS of $2.71, surpassing estimates by 2.03%. However, the stock fell by 3.79% the following day, indicating mixed investor sentiment.
Management Promises & Guidance
Analysts are cautiously optimistic about AbbVie's upcoming earnings, expecting it to meet or slightly exceed EPS and revenue estimates.
Bull Case
If AbbVie beats expectations, it could signal strong demand for its products and effective cost management, potentially boosting investor confidence.
Bear Case
Conversely, if AbbVie misses estimates, it may raise concerns about its product pipeline and market competitiveness, leading to a negative stock reaction.
EPS
$2.69Earnings per share is a critical measure of profitability and will indicate how well AbbVie is managing its costs and revenues.
Revenue
$14.7BTotal revenue gives insight into the company's overall sales performance and market demand for its products.
The print will turn on these two things.
Q1
Will AbbVie achieve or exceed the consensus EPS of $2.69?
This figure is crucial for assessing the company's profitability and could significantly influence investor sentiment.
Q2
What is the outlook for revenue growth, particularly in the immunology segment?
Revenue performance in this area will indicate market demand and the effectiveness of AbbVie's product offerings.
Why consensus could be wrong
The consensus may underestimate AbbVie's revenue potential due to strong demand in its immunology segment, which has shown resilience despite market challenges.
Supporting Evidence
Recent product launches have received positive feedback, indicating higher sales than anticipated.
The company's strong pipeline may not be fully reflected in current estimates, suggesting upside potential.
Options pricing suggests a lower expected move than historical averages, indicating potential for a larger reaction.
Key Risk
If revenue from the immunology segment exceeds $8B, it could significantly alter market perceptions and expectations.
Pre-commit to what would confirm each case.
The market is debating AbbVie's ability to maintain its growth trajectory amidst increasing competition and market pressures.
Bull Confirmed If
An EPS of $2.75 or higher would confirm strong operational performance and market demand.
Bear Confirmed If
An EPS below $2.57 would raise concerns about profitability and growth prospects.
Implied Move
±2.37%
Historical Avg
±3.8%
The options market is pricing in a modest move around the earnings announcement, reflecting uncertainty but not extreme volatility.
Options are pricing ±2.4% while ABBV has averaged ±3.8% over the last 8 prints — setup is pricing cheap.
Likely market behavior by outcome — not investment advice.
Beat & Raise
If AbbVie beats expectations, history suggests a potential stock increase of around 1.56% on the following day, reinforcing positive sentiment.
In-Line / Cautious
An in-line report may lead to a muted reaction, with investors focusing on management's commentary for future guidance.
Miss
If AbbVie misses estimates, the stock could drop by approximately 2.37%, reflecting disappointment in its performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERIZON COMMUNICATIO
Apr 27, 2026